Amsterdam Molecular Therapeutics(in Liquidation) Announces Delisting and Expected Finalisation of Liquidation Process

Informations

• Publié par: amsterdam-molecular-therapeutics-amt-b-v
• Nombre de lectures: 10
• Langue: English

Extrait

Amsterdam Molecular Therapeutics(in Liquidation) Announces Delisting and Expected Finalisation of Liquidation Process

PR Newswire AMSTERDAM, November 6, 2012

AMSTERDAM,November 6, 2012/PRNewswire/ --

Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in liquidatie) (Euronext: AMT) announces that NYSE Euronext has determined and announced that as of19 November 2012, AMT's shares will be delisted from NYSE Euronext in Amsterdam, the Netherlands with16 November 2012being the last trading date.

On12 September 2012, the account and justification (rekening en verantwoording) as prepared by AMT's liquidators was made available for inspection at the Chamber of Commerce of Amsterdam (De Ruyterkade 5, Amsterdam) and at AMT's offices (Meibergdreef 61, Amsterdam Zuidoost), and on14 September 2012notice of the same was given in a national newspaper. Absent any surplus following the final settlement of the remaining assets and liabilities, no plan of distribution (plan van verdeling) was prepared.

Assuming that no action (verzet) will be instituted against the account and justification, AMT's liquidators expect to finalise the liquidation on or shortly following19 November 2012T. There will not be any (final) distributions to AM shareholders in the context of the finalisation of the liquidation or otherwise. When the liquidation ends, AMT and its shares shall cease to exist.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on current expectations only. Undue reliance should not be placed on these statem ents because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT (in liquidation). Actual results could differ materially from current expectations due to a number of factors and uncertainties. AMT (in liquidation) expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.

Further information on AMT (in liquidation), can be found on AMT (in liquidation)'s website http://www.amtbiopharma.com.

PRN NLD